Global Osteoporosis Drugs Market 2019-2023
- Published: Mar 2019
- Pages: 122
- SKU: IRTNTR31009
The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!
- 2500.00
- USD
Industry Insights
The global osteoporosis drugs market size will grow by USD 1.85 billion during 2019-2023 at a CAGR of nearly 5%. The new drug approvals and favorable pipeline and the development of transdermal drug delivery system are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by product (antiresorptive drugs and anabolic drugs) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including Amgen Inc., Eli Lilly and Company, Novartis AG, Pfizer Inc., and Radius Health, Inc.
Osteoporosis is a bone disease that increases the risk of fractures in the hip, wrist, or spine. It can be treated with antiresorptive drugs and anabolic drugs. Antiresorptive drugs restore the bone density by decreasing bone remodeling, whereas anabolic drugs improve the osteoblast activity or increase the osteoblast number.
Key Insights from Osteoporosis Drugs Market – Global Forecast 2019-2023
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the osteoporosis drugs market report
Osteoporosis is caused by low bone mass and tissue loss, which increases the risk of fracture, especially in the spine and wrists. For the effective treatment of the disease, vendors are focusing on the adoption of more targeted approaches such as anabolic medications. Anabolic agents promote new bone formation, improve bone quality and increases its mass, and reduce fracture incidence. The anabolic agent developed by Radium Health Inc, for the treatment of osteoporosis in postmenopausal women and the anabolic agent developed for treating osteoporosis associated with sustained systemic glucocorticoid therapy, are already approved by the US FDA. Companies such as Amgen Inc, and Astellas Pharma Inc., are also focusing on developing a bone-forming monoclonal antibody for the treatment of osteoporosis in patients at high risk of fracture. In addition to drug approvals, the presence of a favorable drug pipeline for osteoporosis will drive osteoporosis drugs market growth in the coming years.
Despite the potential effects of some drugs, the mode of administration is limited. This is driving the need to provide patients with a new route of administration for effective drug delivery. Consequently, researchers have come up with the transdermal drug delivery system that ensures the availability of drugs to the targeted site for prolonged action. The development of transdermal drug delivery system to facilitate the administration of these drugs will be one of the key trends that will gain traction in the coming years. This coupled with new drug approvals will drive osteoporosis drugs market growth at a CAGR of almost 5% during the forecast period.
Industry Analysis
Quantitative Data
|
Qualitative Data
|
Product Insights
The product segment has been segregated into antiresorptive drugs and anabolic drugs. The antiresorptive drugs segment accounted for the highest osteoporosis drugs market share in 2018. During the forecast period, this segment will grow at a slower pace than the overall market. The anabolic drugs segment will grow at a faster pace than the overall market.
The antiresorptive drugs market segment will account for the highest osteoporosis drugs market share in the coming years because of the growing prevalence of osteoporosis and the availability of antiresorptive drugs for treatment.
Regional Insights
North America accounted for the highest market share in 2018. Though the market’s growth in this region will be slower than the growth of the market in Asia, Europe, and ROW, the region will account for the largest osteoporosis drugs market share throughout the forecast period. The US is a key market for osteoporosis drugs in this region.
The growing incidence and prevalence of osteoporosis, strong presence of major vendors and the increased patient access to reimbursement schemes are the primary reasons for the high growth of the osteoporosis drugs market size in this region.
Top Osteoporosis Drugs Manufacturers
The osteoporosis drugs market is moderately fragmented. To help clients improve their position, this osteoporosis drugs market analysis report provides information on the competitive landscape and the products offered by various companies. Moreover, this osteoporosis drugs market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.
The report offers a detailed analysis of several leading osteoporosis drugs manufacturers, including:
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
Segments Covered in the Report
Osteoporosis drugs market by product
- Antiresorptive drugs
- Anabolic drugs
Osteoporosis drugs market by region
- Asia
- Europe
- North America
- ROW
Key Highlights of the Osteoporosis Drugs Market Forecast Report for the Period 2019-2023
- CAGR of the market during the forecast period 2019-2023
- Detailed information on factors that will accelerate the growth of the osteoporosis drugs market size during the next five years
- Precise estimation of the global osteoporosis drugs market size and its contribution to the parent market
- Accurate predictions on upcoming trends and changes in consumer behavior
- The growth of the osteoporosis drugs industry across Asia, Europe, North America, and ROW
- A thorough analysis of the market’s competitive landscape and detailed information on several vendors
- Comprehensive details of factors that will challenge the growth of osteoporosis drugs companies
We can help! Our analysts can customize the market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1 Preface
- 2.2 Preface
- 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Antiresorptive drugs - Market size and forecast 2018-2023
- Anabolic drugs - Market size and forecast 2018-2023
- Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
- Market trends
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Amgen Inc.
- Eli Lilly and Company
- Novartis AG
- Pfizer Inc.
- Radius Health, Inc.
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
- Manufacturers and suppliers
- Channel partners
- Industry experts
- Strategic decision makers
Secondary sources
- Industry journals and periodicals
- Government data
- Financial reports of key industry players
- Historical data
- Press releases

DATA ANALYSIS
Data Synthesis
- Collation of data
- Estimation of key figures
- Analysis of derived insights
Data Validation
- Triangulation with data models
- Reference against proprietary databases
- Corroboration with industry experts

REPORT WRITING
Qualitative
- Market drivers
- Market challenges
- Market trends
- Five forces analysis
Quantitative
- Market size and forecast
- Market segmentation
- Geographical insights
- Competitive landscape
Subscribe & Save
Get lifetime access to our
Technavio Insights
Want to customize this report?
This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.
